$0.77
-$0.08 (-9.61%)
$0.76Day Range$0.88
Key Statistics
Market Cap
$108.42M
Shares Outstanding
127.3M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Nov 20, 2018
Round Lot
100
Locale
US
Trading Data
Day Open
$0.85
Day High
$0.88
Day Low
$0.76
Volume
852.7K
VWAP
$0.81
Prev Close
$0.85
Transactions
--
Acc. Volume
--
About Tiziana Life Sciences Ltd. Common Shares
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.
Identifiers
- CIK
- 0001723069
- Ticker Root
- TLSA
About Tiziana Life Sciences Ltd. Common Shares (TLSA) Stock
Tiziana Life Sciences Ltd. Common Shares (TLSA) closed the 2026-09-16 session at $0.77, down 9.61% versus the previous close (-0.08). The stock opened at $0.85 and traded between $0.76 and $0.88 during that session. Session trading volume was 853K shares. The volume-weighted average price (VWAP) is $0.81.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.
Tiziana Life Sciences Ltd. Common Shares has a market capitalization of $108.4 million. TLSA is listed on the XNAS exchange. The company employs approximately 10 people. The recorded listing date is 2018-11-20.
On this page you can find market TLSA stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors.